Disclosure of payments made to HCPs in Malta
Cooperation between pharmaceutical companies, regulators, Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet disparate patient and public health needs.
Under the EFPIA Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
Disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.
Our disclosures for Malta
The links below will take you to our disclosures for Malta in line with the EFPIA code and the Pharmaceutical Research-Based Industry Malta Association (PRIMA) code, and to a note on the methodology used to set out the data in the report.
Media enquiries: Please contact Marianne Chetcuti, Market Access Manager or Adrian Agius, Ethics & Compliance Officer E-mail: email@example.com Tel: +356 21238131